X

Trial Profile

A Phase Ib/II Clinical Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors to Adult Patients With Advanced Cancers

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Napabucasin (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
Indications Cancer
Focus Adverse reactions
Sponsors Boston Biomedical; Sumitomo Dainippon Pharma Oncology; Sumitomo Pharma America

Most Recent Events

27 Apr 2021 Status changed from active, no longer recruiting to completed.
22 Jan 2021 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
22 Jan 2021 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com